MCID: TRY001
MIFTS: 55

Trypanosomiasis

Categories: Infectious diseases

Aliases & Classifications for Trypanosomiasis

MalaCards integrated aliases for Trypanosomiasis:

Name: Trypanosomiasis 12 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10113
ICD9CM 36 086 086.9
MeSH 45 D014352
SNOMED-CT 69 78940002
ICD10 34 B57.2
UMLS 74 C0041227

Summaries for Trypanosomiasis

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans.

MalaCards based summary : Trypanosomiasis is related to sleeping sickness and chagas disease. An important gene associated with Trypanosomiasis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Aspirin and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are cellular and hematopoietic system

Wikipedia : 77 Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic... more...

Related Diseases for Trypanosomiasis

Diseases related to Trypanosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 sleeping sickness 33.6 AMD1 APOL1 HP HPR IL10 IL6
2 chagas disease 32.9 CCL2 CXCL8 IFNG IL10 IL1B IL2
3 leishmaniasis 30.8 IFNG IL10 IL1B IL4 TLR2 TLR9
4 glomerulonephritis 30.4 ALB CCL2 IL1B TLR9
5 endomyocardial fibrosis 30.4 IL10 IL4 TNF
6 transverse myelitis 30.3 CXCL8 IL10 IL6 TNF
7 mouth disease 30.3 IFNG IL10 IL1B IL6 TLR9 TNF
8 filarial elephantiasis 30.2 IL10 IL4 TLR2 TLR9
9 schistosomiasis 30.2 ALB IFNG IL10 IL2 IL4 TNF
10 uveitis 30.1 CCL2 IFNG IL10 IL4 TNF
11 toxoplasmosis 30.0 IFNG IL10 IL1B IL4 IL6 TLR2
12 human immunodeficiency virus infectious disease 29.9 IFNG IL10 IL2 IL6 TLR9 TNF
13 acquired immunodeficiency syndrome 29.9 ALB IFNG IL10 IL1B IL2 IL6
14 leprosy 3 29.9 IFNG IL10 IL2 TLR2 TNF
15 parasitic helminthiasis infectious disease 29.9 IL10 IL2 IL4 TLR9 TNF
16 filariasis 29.8 ALB IFNG IL10 IL2 IL6 TLR2
17 cutaneous leishmaniasis 29.8 IFNG IL10 IL4 TLR2 TLR9 TNF
18 myeloma, multiple 29.7 ALB CXCL8 IL2 IL6 TLR9 TNF
19 brucellosis 29.6 CXCL8 IFNG IL10 IL2 IL4 IL6
20 malaria 29.2 ALB CCL2 CXCL8 HP IDO1 IFNG
21 visceral leishmaniasis 29.2 ALB CXCL8 IFNG IL10 IL2 IL4
22 trypanosomiasis, human east-african 12.4
23 trypanosomiasis, human west-african 12.1
24 eastern equine encephalitis 11.1
25 punctate inner choroidopathy 10.5 IL10 TNF
26 scorpion envenomation 10.5 IL6 TNF
27 cephalosporin allergy 10.5 IFNG IL10
28 autoimmune myocarditis 10.5 IFNG IL6 TNF
29 staphylococcal toxic shock syndrome 10.5 IFNG IL1B TNF
30 multicentric castleman disease 10.5 IFNG IL10 IL6
31 castleman disease 10.5 IFNG IL10 IL6
32 trachoma 10.5 IDO1 IL10 TNF
33 eye lymphoma 10.5 IL10 IL6 TLR9
34 spotted fever 10.5 IFNG IL10 TNF
35 mucocutaneous leishmaniasis 10.5 IL10 TLR9 TNF
36 hand, foot and mouth disease 10.5 IFNG IL10 IL6
37 glossitis 10.5 IL1B IL6 TNF
38 laryngitis 10.5 IL1B IL6 TNF
39 post-transplant lymphoproliferative disease 10.5 IL10 IL6 TNF
40 fungal meningitis 10.5 CCL2 IFNG IL10
41 exudative glomerulonephritis 10.5 CXCL8 IL1B TNF
42 acute vascular insufficiency of intestine 10.5 IL1B IL6 TNF
43 acute transverse myelitis 10.5 CXCL8 IL10 IL6
44 osteosclerotic myeloma 10.5 IL1B IL6 TNF
45 poems syndrome 10.5 IL1B IL6 TNF
46 listeriosis 10.5 IDO1 IL6 TNF
47 recurrent corneal erosion 10.4 CXCL8 IL1B IL6
48 bagassosis 10.4 CXCL8 IL1B IL6
49 leukomalacia 10.4 IL6 TNF
50 joint disorders 10.4 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Trypanosomiasis:



Diseases related to Trypanosomiasis

Symptoms & Phenotypes for Trypanosomiasis

MGI Mouse Phenotypes related to Trypanosomiasis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 ALB HP IDO1 IFNG IL10 IL2
2 hematopoietic system MP:0005397 10.18 HP IDO1 IFNG IL10 IL1B IL2
3 homeostasis/metabolism MP:0005376 10.18 ALB HP IDO1 IFNG IL10 IL1B
4 immune system MP:0005387 10.13 CCL2 HP IDO1 IFNG IL10 IL1B
5 digestive/alimentary MP:0005381 10.09 ALB IFNG IL10 IL2 IL4 IL6
6 mortality/aging MP:0010768 9.97 ALB HP IFNG IL10 IL1B IL2
7 liver/biliary system MP:0005370 9.96 ALB HP IFNG IL10 IL2 IL4
8 neoplasm MP:0002006 9.61 ALB HP IFNG IL10 IL1B IL2
9 renal/urinary system MP:0005367 9.28 ALB HP IDO1 IFNG IL4 IL6

Drugs & Therapeutics for Trypanosomiasis

Drugs for Trypanosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Warfarin Approved Phase 4 81-81-2 54678486 6691
6
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 70-26-8, 3184-13-2 6262
7
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
8 Nifurtimox Investigational Phase 4,Phase 3,Phase 2,Phase 1 23256-30-6
9
Coumarin Experimental Phase 4 91-64-5 323
10 Antipyretics Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Platelet Aggregation Inhibitors Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Antirheumatic Agents Phase 4,Phase 2
15 Fibrinolytic Agents Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Analgesics Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Peripheral Nervous System Agents Phase 4,Phase 3
20 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Benzonidazole Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Adrenergic Agents Phase 4,Phase 3
27 Neurotransmitter Agents Phase 4,Phase 3
28 Protective Agents Phase 4,Phase 3
29 Adrenergic alpha-Antagonists Phase 4
30 HIV Protease Inhibitors Phase 4
31 Adrenergic alpha-1 Receptor Antagonists Phase 4
32 Antihypertensive Agents Phase 4,Phase 3
33 Vasodilator Agents Phase 4,Phase 3,Not Applicable
34 Natriuretic Peptide, Brain Phase 4
35 calcium channel blockers Phase 4
36 Adrenergic Antagonists Phase 4,Phase 3
37 Calcium, Dietary Phase 4
38 Antioxidants Phase 4,Phase 3
39 Adrenergic beta-Antagonists Phase 4,Phase 3
40 Angiotensin-Converting Enzyme Inhibitors Phase 4
41 Hormones Phase 4,Phase 2
42
protease inhibitors Phase 4
43 Anticoagulants Phase 4
44
Bisoprolol Approved Phase 3 66722-44-9 2405
45
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
46
Amiodarone Approved, Investigational Phase 3,Not Applicable 1951-25-3 2157
47
Coal tar Approved Phase 3 8007-45-2
48 Melarsoprol Investigational Phase 3 494-79-1
49 Adrenergic beta-1 Receptor Antagonists Phase 3
50 Sympatholytics Phase 3

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
2 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
3 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
4 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Completed NCT01678599 Phase 4 Benznidazole
5 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
6 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
7 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
8 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
9 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
10 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
11 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
12 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
13 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
14 Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
15 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
16 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
17 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
18 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
19 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
20 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
21 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
22 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
23 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
24 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
25 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
26 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Not yet recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
27 Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
28 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
29 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
30 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
31 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
32 Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
33 A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
34 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
35 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
36 Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
37 Colchicine for Patients With Chagas´ Disease( B1 Stage) Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
38 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
39 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
40 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
41 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Completed NCT00982904 Phase 1 Fexinidazole/Placebo
42 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Completed NCT01533961 Phase 1 SCYX-7158;Placebo
43 Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation Completed NCT02571062 Phase 1 Fexinidazole
44 Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions Completed NCT01340157 Phase 1 Fexinidazole
45 Pharmacokinetic Drug-Drug Interaction Study Completed NCT03892213 Phase 1 Benznidazole;E1224
46 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
47 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
48 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
49 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
50 Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo

Search NIH Clinical Center for Trypanosomiasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: trypanosomiasis

Genetic Tests for Trypanosomiasis

Anatomical Context for Trypanosomiasis

MalaCards organs/tissues related to Trypanosomiasis:

42
Testes, Brain, T Cells, B Cells, Eye, Spleen, Endothelial

Publications for Trypanosomiasis

Articles related to Trypanosomiasis:

(show top 50) (show all 1868)
# Title Authors Year
1
Association between IL1 gene polymorphism and human African trypanosomiasis in populations of sleeping sickness foci of southern Cameroon. ( 30908482 )
2019
2
Trans-sialidase Protein as a Potential Serological Marker for African Trypanosomiasis. ( 30604107 )
2019
3
Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. ( 30655955 )
2019
4
Human African Trypanosomiasis: Progress and Stagnation. ( 30712768 )
2019
5
Integration of Human African Trypanosomiasis Control Activities into Primary Health Services in the Democratic Republic of the Congo: A Qualitative Study of Stakeholder Perceptions. ( 30719963 )
2019
6
Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis. ( 30740102 )
2019
7
Novel Minor Groove Binders cure animal African trypanosomiasis in an in vivo mouse model. ( 30763102 )
2019
8
Parasite specific 7SL-derived small RNA is an effective target for diagnosis of active trypanosomiasis infection. ( 30779758 )
2019
9
Community-led data collection using Open Data Kit for surveillance of animal African trypanosomiasis in Shimba hills, Kenya. ( 30885271 )
2019
10
Indigofera oblongifolia protects against trypanosomiasis-induced spleen injury. ( 30898472 )
2019
11
QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski's descriptors. ( 30899832 )
2019
12
Safety and efficacy of three trypanocides in confirmed field cases of trypanosomiasis in working equines in The Gambia: a prospective, randomised, non-inferiority trial. ( 30901321 )
2019
13
American trypanosomiasis and Chagas disease: Sexual transmission. ( 30664986 )
2019
14
American Trypanosomiasis (Chagas Disease). ( 30712757 )
2019
15
Major kinds of drug targets in Chagas disease or American Trypanosomiasis. ( 31020939 )
2019
16
Trypanosoma brucei Interaction with Host: Mechanism of VSG Release as Target for Drug Discovery for African Trypanosomiasis. ( 30934540 )
2019
17
First report of trypanosomiasis in farmed largemouth bass (Micropterus salmoides) from China: pathological evaluation and taxonomic status. ( 31049695 )
2019
18
Factors associated with persistence of African animal trypanosomiasis in Lango subregion, northern Uganda. ( 31054060 )
2019
19
Case Report: Trypanosoma brucei Gambiense Human African Trypanosomiasis as the Cause of Fever in an Inpatient with Multiple Myeloma and HIV-1 Coinfection. ( 31074413 )
2019
20
Human African trypanosomiasis: How do the parasites enter and cause dysfunctions of the nervous system in murine models? ( 29870779 )
2019
21
Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. ( 30453246 )
2018
22
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
23
FDG PET/CT in a Case of Human African Trypanosomiasis (Sleeping Sickness). ( 29863573 )
2018
24
Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis. ( 29744736 )
2018
25
Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. ( 29701144 )
2018
26
Parasitological and Molecular Detection of Canine Trypanosomiasis From Riyadh Province, Saudi Arabia. ( 29990441 )
2018
27
Integrating innovations: a qualitative analysis of referral non-completion among rapid diagnostic test-positive patients in Uganda's human African trypanosomiasis elimination programme. ( 30119700 )
2018
28
Clinical management of East African trypanosomiasis in South Africa: Lessons learned. ( 30153486 )
2018
29
The activity of Artemisia spp. and their constituents against Trypanosomiasis. ( 30166103 )
2018
30
A systematic review and meta-analysis of small ruminant and porcine trypanosomiasis prevalence in sub-Saharan Africa (1986 to 2018). ( 30179607 )
2018
31
The Long Wait for a New Drug for Human African Trypanosomiasis. ( 30181071 )
2018
32
Molecular detection of equine trypanosomiasis in the Riyadh Province of Saudi Arabia. ( 30204053 )
2018
33
Innovative digital technologies for quality assurance of diagnosis of human African trypanosomiasis. ( 30212459 )
2018
34
Cost-effectiveness of using a rapid diagnostic test to screen for human African trypanosomiasis in the Democratic Republic of the Congo. ( 30240406 )
2018
35
Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan. ( 30273342 )
2018
36
Climate change and African trypanosomiasis vector populations in Zimbabwe's Zambezi Valley: A mathematical modelling study. ( 30346952 )
2018
37
A meta-analysis of the prevalence of bovine trypanosomiasis in some African countries from 2000 to 2018. ( 30388996 )
2018
38
Exploring the effect of human and animal population growth on vector-borne disease transmission with an agent-based model of Rhodesian human African trypanosomiasis in eastern province, Zambia. ( 30408045 )
2018
39
Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China. ( 30423460 )
2018
40
The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. ( 30521522 )
2018
41
Monitoring the elimination of human African trypanosomiasis: Update to 2016. ( 30521525 )
2018
42
Improvement of Aqueous Solubility of Lapatinib-derived Analogs: Identification of a Quinolinimine as a Lead for Human African Trypanosomiasis Drug Development. ( 30565932 )
2018
43
Modelling appropriate use of trypanocides to restrict wide-spread multi-drug resistance during chemotherapy of animal African trypanosomiasis. ( 30567619 )
2018
44
Mathematical Modelling of Human African Trypanosomiasis Using Control Measures. ( 30595713 )
2018
45
Therapeutics against Trypanosomiasis. ( 30698105 )
2018
46
Applying Loop-mediated Isothermal Amplification (LAMP) in the Diagnosis of Malaria, Leishmaniasis and Trypanosomiasis as Point-of-Care Tests (POCTs). ( 30360713 )
2018
47
Advanced in silico methods for the development of anti-leishmaniasis and anti-trypanosomiasis agents. ( 30378482 )
2018
48
MRI findings of the brain in human African trypanosomiasis: a case series and review of the literature. ( 30931144 )
2018
49
Bovine and small ruminant African animal trypanosomiasis in Nigeria - A review. ( 31014888 )
2018
50
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. ( 29113731 )
2018

Variations for Trypanosomiasis

Expression for Trypanosomiasis

Search GEO for disease gene expression data for Trypanosomiasis.

Pathways for Trypanosomiasis

Pathways related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 CCL2 CXCL8 HP IFNG IL10 IL1B
2
Show member pathways
13.75 CCL2 CXCL8 IFNG IL10 IL1B IL2
3
Show member pathways
13.64 CCL2 CXCL8 IFNG IL10 IL1B IL2
4
Show member pathways
13.54 CCL2 CXCL8 IL10 IL1B IL2 IL4
5
Show member pathways
13.47 CCL2 CXCL8 IFNG IL10 IL1B IL2
6
Show member pathways
13.4 CCL2 CXCL8 IL10 IL1B IL2 IL4
7
Show member pathways
13.28 IFNG IL1B IL2 IL4 TLR2 TLR9
8
Show member pathways
13.23 CCL2 CXCL8 IFNG IL10 IL1B IL2
9
Show member pathways
13.03 CCL2 CXCL8 IL1B IL6 TLR2 TNF
10
Show member pathways
13.02 CXCL8 IFNG IL10 IL1B IL2 IL4
11 12.88 CXCL8 IFNG IL2 IL4 IL6
12
Show member pathways
12.82 CXCL8 IFNG IL1B IL6 TNF
13
Show member pathways
12.82 IL1B IL2 IL6 TLR2 TLR9 TNF
14
Show member pathways
12.76 IFNG IL10 IL1B IL2 IL4 IL6
15
Show member pathways
12.75 CCL2 IFNG IL10 IL1B IL2 IL6
16
Show member pathways
12.72 IFNG IL10 IL1B IL2 IL4 IL6
17
Show member pathways
12.7 IFNG IL10 IL2 IL4 TNF
18 12.58 CCL2 IDO1 IFNG IL10 IL1B IL2
19
Show member pathways
12.51 IFNG IL10 IL2 IL4 IL6
20
Show member pathways
12.49 ALB CCL2 IFNG IL1B IL2 IL4
21
Show member pathways
12.48 CCL2 CXCL8 IFNG IL1B IL4 IL6
22
Show member pathways
12.43 IFNG IL10 IL1B IL4 TLR2 TNF
23
Show member pathways
12.42 CXCL8 IFNG IL1B IL6 TNF
24
Show member pathways
12.42 CXCL8 IFNG IL10 IL1B IL2 IL4
25 12.4 IFNG IL10 IL1B IL6 TLR2 TLR9
26
Show member pathways
12.39 CXCL8 IL6 TLR2 TLR9 TNF
27
Show member pathways
12.37 IL10 IL1B IL2 IL6 TLR9 TNF
28
Show member pathways
12.36 CXCL8 IL1B IL6 TLR2 TNF
29 12.32 IFNG IL6 TLR2 TLR9 TNF
30 12.32 CXCL8 IL10 IL1B IL6 TNF
31
Show member pathways
12.3 CXCL8 IFNG IL1B IL4 IL6 TLR2
32
Show member pathways
12.24 CCL2 CXCL8 IFNG IL10 IL1B IL2
33
Show member pathways
12.22 IFNG IL1B IL4 IL6 TLR2 TNF
34 12.19 CCL2 IFNG IL1B TNF
35 12.17 IFNG IL10 IL2 IL4 IL6 TNF
36
Show member pathways
12.15 IFNG IL10 IL1B IL2 IL6 TLR2
37 12.14 CCL2 CXCL8 IL10 IL1B IL4 IL6
38
Show member pathways
12.13 IL1B IL2 TLR2 TLR9
39
Show member pathways
12.09 IFNG IL1B IL2 IL4
40 12.09 CCL2 CXCL8 IFNG IL1B IL2 IL4
41 12.08 CCL2 CXCL8 IL1B IL6 TNF
42 12.07 CCL2 IL1B IL6 TNF
43 12.06 CXCL8 IFNG IL1B IL6
44
Show member pathways
12.05 ALB APOL1 HP HPR
45 12.04 CXCL8 IFNG IL10 IL1B IL6 TLR2
46 12.01 IL1B IL4 IL6 TNF
47 12 CCL2 CXCL8 IFNG IL1B IL6 TLR2
48 11.99 IFNG IL10 IL2 IL6
49 11.98 CXCL8 IFNG IL2 IL4 IL6
50 11.96 CXCL8 IFNG IL1B IL6

GO Terms for Trypanosomiasis

Cellular components related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 ALB APOL1 CCL2 CXCL8 HP HPR
2 blood microparticle GO:0072562 9.55 ALB APOL1 HP HPR KNG1
3 extracellular space GO:0005615 9.47 ALB APOL1 CCL2 CXCL8 HP HPR

Biological processes related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL1B IL6 TLR2 TLR9 TNF
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL6 TNF
3 response to organic substance GO:0010033 9.93 HP HPR IL10 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.93 CCL2 CXCL8 IL10 IL1B IL6 TNF
5 positive regulation of inflammatory response GO:0050729 9.92 IL2 TLR2 TLR9 TNF
6 neutrophil chemotaxis GO:0030593 9.91 CCL2 CXCL8 IL1B
7 positive regulation of JNK cascade GO:0046330 9.91 IL1B TLR9 TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 IFNG IL2 IL4 IL6
9 cellular response to organic cyclic compound GO:0071407 9.9 CCL2 IL1B TNF
10 regulation of insulin secretion GO:0050796 9.9 IFNG IL1B TNF
11 positive regulation of T cell proliferation GO:0042102 9.88 IL1B IL2 IL4 IL6
12 humoral immune response GO:0006959 9.87 CCL2 IFNG IL6 TNF
13 positive regulation of interferon-gamma production GO:0032729 9.86 IL1B IL2 TNF
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IFNG IL1B TNF
15 cytokine-mediated signaling pathway GO:0019221 9.86 CCL2 CXCL8 IL10 IL1B IL2 IL4
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL1B TLR2 TLR9 TNF
17 positive regulation of B cell proliferation GO:0030890 9.84 IL2 IL4 TLR9
18 protein kinase B signaling GO:0043491 9.83 CCL2 IL1B TNF
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 CCL2 IL1B TLR2 TNF
20 negative regulation of interleukin-6 production GO:0032715 9.82 IL10 TLR9 TNF
21 negative regulation of neurogenesis GO:0050768 9.81 IL1B IL6 TNF
22 regulation of signaling receptor activity GO:0010469 9.81 CCL2 CXCL8 IFNG IL10 IL1B IL2
23 positive regulation of interleukin-8 production GO:0032757 9.8 IL1B TLR2 TLR9 TNF
24 positive regulation of glial cell proliferation GO:0060252 9.79 IL1B IL6 TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 IFNG IL1B TNF
26 positive regulation of interleukin-12 production GO:0032735 9.78 IDO1 IFNG TLR2 TLR9
27 response to glucocorticoid GO:0051384 9.77 IL10 IL6 TNF
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 IL10 IL1B TNF
29 positive regulation of interleukin-6 production GO:0032755 9.77 IL1B IL6 TLR2 TLR9 TNF
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.76 CCL2 TLR2 TLR9
31 I-kappaB phosphorylation GO:0007252 9.74 TLR2 TLR9
32 PERK-mediated unfolded protein response GO:0036499 9.74 CCL2 CXCL8
33 polyamine biosynthetic process GO:0006596 9.74 AMD1 ODC1
34 positive regulation of immunoglobulin secretion GO:0051024 9.74 IL2 IL6
35 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B TLR9
36 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR9 TNF
37 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL2 IL4
38 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
39 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
40 polyamine metabolic process GO:0006595 9.72 AMD1 ODC1
41 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IL1B TNF
42 negative regulation of interleukin-8 production GO:0032717 9.71 IL10 TLR9
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL10 IL4
44 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
45 positive regulation of chemokine production GO:0032722 9.71 IL6 TLR2 TLR9 TNF
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 IL10 TNF
47 positive regulation of fever generation GO:0031622 9.7 IL1B TNF
48 positive regulation of interleukin-18 production GO:0032741 9.69 TLR2 TLR9
49 tumor necrosis factor production GO:0032640 9.69 TLR2 TLR9
50 positive regulation of neuroinflammatory response GO:0150078 9.69 IL1B IL6 TNF

Molecular functions related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL4 IL6
2 cytokine activity GO:0005125 9.28 CCL2 CXCL8 IFNG IL10 IL1B IL2
3 signaling pattern recognition receptor activity GO:0008329 9.26 TLR2 TLR9
4 hemoglobin binding GO:0030492 8.96 HP HPR

Sources for Trypanosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....